论文部分内容阅读
作者对12名妇女进行了每天释放炔诺酮(NET)200μg和雌二醇(E_2)140μg的阴道环(NET/E_2 CVR)的临床研究。这些妇女以前曾参加过释放左旋18甲(1-Ng)和E_2的阴道环(1-Ng/E_2CVR)的临床试验,完成1-Ng/E_2 CVR研究后一年多参与本研究,这些妇女有规则的月经,平均年龄27岁(21～36岁)、平均体重59.5kg(50～68.5kg),平均身高165cm(158～175cm),产次0～3次,所有对象均为正常饮食者,未经常用其它药物,也未过量饮酒。所有对象经过一个对照周期后于月经第5天置入NET/E_2 CVR,21天后取出CVR,经7天后重又置入CVR,如此反复使用,每例使用6个周期,在使用3个周期后换一个
The authors conducted a clinical study of 12 women with a daily vaginal ring (NET / E_2 CVR) of 200 μg of norethindrone (NET) and 140 μg of estradiol (E_2). These women had previously participated in the clinical trial of vaginal ring (1-Ng / E_2CVR) releasing 18-nails (1-Ng) and E_2 and participated in the study more than a year after completion of the 1-Ng / E_2 CVR study. These women had Regular menstruation, the average age of 27 years (21 to 36 years old), the average body weight of 59.5kg (50 ~ 68.5kg), the average height of 165cm (158 ~ 175cm), delivery 0-3 times, all subjects were normal diet, Not often used other drugs, nor excessive drinking. All subjects were placed in NET / E_2 CVR on the fifth day of menstruation after one control cycle. CVRs were taken out 21 days later and re-inserted into CVRs after 7 days. Thus, repeated use was performed for 6 cycles for each case. After 3 cycles another